



**Greater Manchester Cancer**

**GM Cancer Board**

**Update in lieu of November 21 meeting**

# H2 Planning Process 2021-22

## Cancer Alliance Role

- System engagement: Represented on all GM Cell discussions, Chief Operating Officers, Provider Federation Board and GMHSP System Planning Co-ordination group
- Design and oversight of GM 'Check & Challenge' process for cancer elements of H2 plans – provider level meetings held and reports produced
- Detailed feedback provided on activity plans
- Cancer Alliance narrative produced and submitted as part of the GM system H2 submission
- Ongoing role to oversee and track delivery of the plans

# H2 Planning Process 2021-22 continued

## Key Messages/Cancer narrative included in the final submission:

- 62 day wait figures for March 2022 exceed the expected baseline therefore don't meet the target – The current position (October 2021) is 1236. It is forecasted that GM will not deliver the baseline by March 2022; it is anticipated there will be a variation of 67 patients
- Cancer Alliance will maintain a single system-level overview of cancer surgery through the continuance of the GM Cancer SitRep and the Cancer PTL and develop to include tracking of first treatments. Oversight of individual providers and GM system through GM Tableau - at pathway, provider and CCG level. Reporting via GM Cell structure - GM Cancer Sitrep (weekly). Targeted approach to allocate support to the areas with the greatest challenge(s).
- Harm reviews: **Ensure that harm reviews are undertaken** on all patients who are treated for cancer more than 104 days following a referral on to a 62 day pathway (or treated after 73 days if on a 31 day pathway). Thematic analysis will inform local and system-level actions to mitigate risks and improve care. Cancer Alliance are devising a process/methodology for Harm Reviews in GM - including clarity for clinicians in the identification and reporting of harm. Working with other Alliances to share best practice and ensure alignment. System level reporting via GM Quality Board and Cell structure
- Plans for 2 Trusts in GM marked as 'red' in terms of delivering national planning guidance in relation to cancer

# Cancer Performance

- Current PTL Size (As of week ending 14.11.21) 15966
- Volume of patients >62 days 1529; 1125 from a 2ww referral source. 47% UGI/LGI. Baseline for H2 – 761 from a 2ww referral source. H2 planning expects GM to be at 828 at end March 22. 67 above the baseline
- Volume of patients >104 days 348; 222 from a 2ww referral source. No official H2 baseline; pre-covid baseline 136
- Referrals at c110% of post-covid levels on average. Significant pressure in LGI & Skin
- P2 Waiting list 1162 in total. 252 awaiting a date
- Latest weekly surgical treatment numbers 289

# Cancer Performance continued

CWT performance – Reporting on September 2021.

Key standards:

|                            |        |
|----------------------------|--------|
| 2ww                        | 86.37% |
| 2ww Breast symptoms        | 66.61% |
| 28 day Faster Diagnosis    | 70.65% |
| 31 Day DTT                 | 94.69% |
| 62 Day Consultant Upgrades | 74.90% |
| 62 Day Screening           | 68.55% |
| 62 Day RTT                 | 69.62% |

The 62 day RTT and 28 day FDS is a deteriorating position. However, comparing with the previous month 24 more patients were treated on the 62 day pathway, and an extra 1582 records had been completed in the FDS standard, improving data completeness and providing a more accurate position.

# Cancer Performance continued

CWT performance – Reporting on September 2021.

Key standards:

|                            |        |
|----------------------------|--------|
| 2ww                        | 86.37% |
| 2ww Breast symptoms        | 66.61% |
| 28 day Faster Diagnosis    | 70.65% |
| 31 Day DTT                 | 94.69% |
| 62 Day Consultant Upgrades | 74.90% |
| 62 Day Screening           | 68.55% |
| 62 Day RTT                 | 69.62% |

The 62 day RTT and 28 day FDS is a deteriorating position. However, comparing with the previous month 24 more patients were treated on the 62 day pathway, and an extra 1582 records had been completed in the FDS standard, improving data completeness and providing a more accurate position.

# Annual Report 2020 - 2021



Greater Manchester Cancer's Annual Report will this year cover a **two year period**.

This accounts for impact on teams in the initial wave of COVID-19.

The report covers all parts of the cancer pathway as per previous years. It is also due to give an update on the 'Taking Charge' document, which detailed our 5 year cancer plan from 2017 – 2021.

The report is almost completed and due for external publication in February 2022.

Note: Images shown are in draft and represent an example of the full report style.

# NHS-Galleri trial update

The screening unit has now completed its run at Oldham and is live in Salford.

Referrals are being managed at present by NCA's Rapid Diagnostic Centre team in the first instance.

A number of participants with Cancer-Signal Origins identified from their bloods have been referred on a 2ww pathway for investigation.

The team held a system-wide information briefing session on 11 November with 70 attendees and over 100 registered.

A copy of the presentation is available to view here:

<https://bit.ly/GalleriGMNov21>


A copy of the Q&As from the session is available to view here: <https://bit.ly/GMGalleriQuestions>



The GM cancer team have also produced a podcast episode about the trial, featuring GRAIL UK's Director of Intelligence, Sara Hiom and local representatives discussing Galleri in further detail.

Spotify: <https://bit.ly/30OImK4>

Apple Podcasts: <https://bit.ly/3r4FT8d>



**Public website: [nhs-galleri.org](https://nhs-galleri.org)**

| Month               | Locality   |
|---------------------|--|
| October 21          | Oldham CCG – Prince Street Car Park                              |
| November 21         | Salford CCG – Tesco, Pendleton Way, Salford                      |
| December 21         | Manchester CCG – Hulme Retail Park                               |
| January 22          | Trafford CCG – Old Trafford Cricket Ground                       |
| February 22 onwards | HMR CCG, Wigan CCG, Bury CCG, Bolton CCG, Stockport CCG, T&G CCG |